232 related articles for article (PubMed ID: 7931827)
41. Serum anti-p53 in relation to mutations across the entire translated p53 gene in colorectal carcinomas.
Forslund A; Kressner U; Lindmark G; Inganäs M; Lundholm K
Int J Oncol; 2001 Sep; 19(3):501-6. PubMed ID: 11494027
[TBL] [Abstract][Full Text] [Related]
42. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms.
O'Neill CJ; Deavers MT; Malpica A; Foster H; McCluggage WG
Am J Surg Pathol; 2005 Aug; 29(8):1034-41. PubMed ID: 16006797
[TBL] [Abstract][Full Text] [Related]
43. Evaluation of four antibodies in detecting p53 protein for predicting clinicopathological and prognostic significance in colorectal adenocarcinoma.
Zhang Hong
Clin Cancer Res; 1999 Dec; 5(12):4126-32. PubMed ID: 10632350
[TBL] [Abstract][Full Text] [Related]
44. P53 expression in synchronous colorectal cancer.
Yalcinkaya U; Ozturk E; Ozgur T; Yerci O; Yilmazlar T
Saudi Med J; 2008 Jun; 29(6):826-31. PubMed ID: 18521459
[TBL] [Abstract][Full Text] [Related]
45. Pancreatic endocrine tumours: evidence for a tumour suppressor pathogenesis and for a tumour suppressor gene on chromosome 17p.
Beghelli S; Pelosi G; Zamboni G; Falconi M; Iacono C; Bordi C; Scarpa A
J Pathol; 1998 Sep; 186(1):41-50. PubMed ID: 9875139
[TBL] [Abstract][Full Text] [Related]
46. p53 protein immunostaining in routinely processed paraffin-embedded sections.
Bruner JM; Connelly JH; Saya H
Mod Pathol; 1993 Mar; 6(2):189-94. PubMed ID: 8483890
[TBL] [Abstract][Full Text] [Related]
47. p53 overexpression and human papillomavirus infection in transitional cell carcinoma of the urinary bladder: correlation with histological parameters.
Tenti P; Zappatore R; Romagnoli S; Civardi E; Giunta P; Scelsi R; Stella G; Carnevali L
J Pathol; 1996 Jan; 178(1):65-70. PubMed ID: 8778319
[TBL] [Abstract][Full Text] [Related]
48. Expression of Bcl-2 in lung neuroendocrine tumours: comparison with p53.
Wang DG; Johnston CF; Sloan JM; Buchanan KD
J Pathol; 1998 Mar; 184(3):247-51. PubMed ID: 9614375
[TBL] [Abstract][Full Text] [Related]
49. p53 Gene alterations and p53 protein accumulation in infiltrating ductal breast carcinomas: correlation between immunohistochemical and molecular biology techniques.
Hurlimann J; Chaubert P; Benhattar J
Mod Pathol; 1994 May; 7(4):423-8. PubMed ID: 8066070
[TBL] [Abstract][Full Text] [Related]
50. P53 mutation analysis of colorectal liver metastases: relation to actual survival, angiogenic status, and p53 overexpression.
de Jong KP; Gouw AS; Peeters PM; Bulthuis M; Menkema L; Porte RJ; Slooff MJ; van Goor H; van den Berg A
Clin Cancer Res; 2005 Jun; 11(11):4067-73. PubMed ID: 15930341
[TBL] [Abstract][Full Text] [Related]
51. Analysis of p53 antibody response in patients with squamous cell carcinoma of the head and neck.
Lavieille JP; Lubin R; Soussi T; Reyt E; Brambilla C; Riva C
Anticancer Res; 1996; 16(4C):2385-8. PubMed ID: 8816839
[TBL] [Abstract][Full Text] [Related]
52. Ki-67, p53 and bcl-2 analysis in colonic versus rectal adenocarcinoma.
Petrişor O; Giuşcă SE; Sajin M; Dobrescu G; Căruntu ID
Rom J Morphol Embryol; 2008; 49(2):163-71. PubMed ID: 18516322
[TBL] [Abstract][Full Text] [Related]
53. The flow cytometric analysis of total p53 protein content and proliferation indices in colorectal cancer, in relation to clinical outcome.
Rew DA; Karkera R; Mullee MA; Julious SA; Wilson GD
Eur J Surg Oncol; 1996 Oct; 22(5):508-15. PubMed ID: 8903495
[TBL] [Abstract][Full Text] [Related]
54. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies.
Bártek J; Bártková J; Vojtĕsek B; Stasková Z; Lukás J; Rejthar A; Kovarík J; Midgley CA; Gannon JV; Lane DP
Oncogene; 1991 Sep; 6(9):1699-703. PubMed ID: 1923535
[TBL] [Abstract][Full Text] [Related]
55. Expression of the nuclear oncogene p53 in colon tumours.
van den Berg FM; Tigges AJ; Schipper ME; den Hartog-Jager FC; Kroes WG; Walboomers JM
J Pathol; 1989 Mar; 157(3):193-9. PubMed ID: 2926561
[TBL] [Abstract][Full Text] [Related]
56. Evaluation of p53 protein expression as a marker for long-term prognosis in colorectal carcinoma.
Mulder JW; Baas IO; Polak MM; Goodman SN; Offerhaus GJ
Br J Cancer; 1995 Jun; 71(6):1257-62. PubMed ID: 7779721
[TBL] [Abstract][Full Text] [Related]
57. Lack of detection of p53 expression in retinoblastoma tumor cells.
Faraldi F; Calzolari A; Alfieri E; Mincione GP; Mincione F
Pathologica; 1994 Aug; 86(4):401-2. PubMed ID: 7708441
[TBL] [Abstract][Full Text] [Related]
58. Production of human p53 specific monoclonal antibodies and their use in immunohistochemical studies of tumor cells.
Legros Y; Lacabanne V; d'Agay MF; Larsen CJ; Pla M; Soussi T
Bull Cancer; 1993 Feb; 80(2):102-10. PubMed ID: 7513565
[TBL] [Abstract][Full Text] [Related]
59. p53 mutant gene expression in paraffin embedded and fresh frozen tissue of different urogenital tumors.
Kuczyk MA; Allhoff EP; Serth J; Hervatin C; Jonas U
Investig Urol (Berl); 1994; 5():12-5. PubMed ID: 7719291
[No Abstract] [Full Text] [Related]
60. The cellular protein p53 in human tumours.
Crawford LV; Pim DC; Lamb P
Mol Biol Med; 1984 Aug; 2(4):261-72. PubMed ID: 6544917
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
